Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Conditions: Lung Cancer; Extensive-stage Small-cell Lung Cancer Interventions: Radiation: Low-dose radiotherapy; Drug: Etoposide; Drug: Cisplatin; Drug: Sugemalimab; Drug: Olaparib Sponsors: Sichuan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials